<?xml version='1.0' encoding='utf-8'?>
<document id="32233814"><sentence text="Influence of astragaloside IV on pharmacokinetics of triptolide in rats and its potential mechanism."><entity charOffset="53-63" id="DDI-PubMed.32233814.s1.e0" text="triptolide" /></sentence><sentence text="Context: It is common to combine two or more drugs in clinics in China" /><sentence text=" Triptolide (TP) has been used primarily for the treatment of inflammatory and autoimmune diseases"><entity charOffset="1-11" id="DDI-PubMed.32233814.s3.e0" text="Triptolide" /><entity charOffset="13-15" id="DDI-PubMed.32233814.s3.e1" text="TP" /><pair ddi="false" e1="DDI-PubMed.32233814.s3.e0" e2="DDI-PubMed.32233814.s3.e0" /><pair ddi="false" e1="DDI-PubMed.32233814.s3.e0" e2="DDI-PubMed.32233814.s3.e1" /></sentence><sentence text=" Astragaloside IV (AS-IV) has been applied with many other drugs, due to its various pharmacological effects"><entity charOffset="1-17" id="DDI-PubMed.32233814.s4.e0" text="Astragaloside IV" /></sentence><sentence text=" AS-IV and TP can be used together for the treatment of diseases in clinics in China"><entity charOffset="11-26" id="DDI-PubMed.32233814.s5.e0" text="TP" /></sentence><sentence text="Objective: This study investigates the effects of astragaloside IV (AS-IV) on the pharmacokinetics of TP in rats and its potential mechanism"><entity charOffset="50-66" id="DDI-PubMed.32233814.s6.e0" text="astragaloside IV" /><entity charOffset="68-73" id="DDI-PubMed.32233814.s6.e1" text="AS-IV" /><entity charOffset="102-106" id="DDI-PubMed.32233814.s6.e2" text="TP" /><pair ddi="false" e1="DDI-PubMed.32233814.s6.e0" e2="DDI-PubMed.32233814.s6.e0" /><pair ddi="false" e1="DDI-PubMed.32233814.s6.e0" e2="DDI-PubMed.32233814.s6.e1" /><pair ddi="false" e1="DDI-PubMed.32233814.s6.e0" e2="DDI-PubMed.32233814.s6.e2" /><pair ddi="false" e1="DDI-PubMed.32233814.s6.e1" e2="DDI-PubMed.32233814.s6.e1" /><pair ddi="false" e1="DDI-PubMed.32233814.s6.e1" e2="DDI-PubMed.32233814.s6.e2" /></sentence><sentence text="Materials and methods: The pharmacokinetics of orally administered triptolide (2 mg/kg) with or without AS-IV pre-treatment (100 mg/kg/day for 7 d) were investigated"><entity charOffset="67-77" id="DDI-PubMed.32233814.s7.e0" text="triptolide" /><entity charOffset="104-113" id="DDI-PubMed.32233814.s7.e1" text="AS-IV" /><pair ddi="false" e1="DDI-PubMed.32233814.s7.e0" e2="DDI-PubMed.32233814.s7.e0" /><pair ddi="false" e1="DDI-PubMed.32233814.s7.e0" e2="DDI-PubMed.32233814.s7.e1" /></sentence><sentence text=" Additionally, the effects of AS-IV on the transport of triptolide were investigated using the Caco-2 cell transwell model"><entity charOffset="56-66" id="DDI-PubMed.32233814.s8.e0" text="triptolide" /><entity charOffset="30-39" id="DDI-PubMed.32233814.s8.e1" text="AS-IV" /><pair ddi="false" e1="DDI-PubMed.32233814.s8.e1" e2="DDI-PubMed.32233814.s8.e1" /><pair ddi="false" e1="DDI-PubMed.32233814.s8.e1" e2="DDI-PubMed.32233814.s8.e0" /></sentence><sentence text="Results: The results indicated that when the rats were pre-treated with AS-IV, the Cmax of triptolide decreased from 418"><entity charOffset="91-101" id="DDI-PubMed.32233814.s9.e0" text="triptolide" /><entity charOffset="72-81" id="DDI-PubMed.32233814.s9.e1" text="AS-IV" /><pair ddi="false" e1="DDI-PubMed.32233814.s9.e1" e2="DDI-PubMed.32233814.s9.e1" /><pair ddi="false" e1="DDI-PubMed.32233814.s9.e1" e2="DDI-PubMed.32233814.s9.e0" /></sentence><sentence text="78 ± 29" /><sentence text="36 to 351" /><sentence text="31 ± 38" /><sentence text="88 ng/mL, and the AUC0-t decreased from 358" /><sentence text="83 ± 19" /><sentence text="56 to 252" /><sentence text="23 ± 15" /><sentence text="75 μg/h/L" /><sentence text=" The Caco-2 cell transwell experiments indicated that AS-IV could increase the efflux ratio of TP from 2"><entity charOffset="95-99" id="DDI-PubMed.32233814.s18.e0" text="TP" /><entity charOffset="54-58" id="DDI-PubMed.32233814.s18.e1" text="AS-IV" /><pair ddi="false" e1="DDI-PubMed.32233814.s18.e1" e2="DDI-PubMed.32233814.s18.e1" /><pair ddi="false" e1="DDI-PubMed.32233814.s18.e1" e2="DDI-PubMed.32233814.s18.e0" /></sentence><sentence text="37 to 2" /><sentence text="91 through inducing the activity of P-gp" /><sentence text="Discussion and conclusions: In conclusion, AS-IV could decrease the system exposure of triptolide when they are co-administered, and it might work through decreasing the absorption of triptolide by inducing the activity of P-gp"><entity charOffset="87-97" id="DDI-PubMed.32233814.s21.e0" text="triptolide" /><entity charOffset="184-194" id="DDI-PubMed.32233814.s21.e1" text="triptolide" /><entity charOffset="43-52" id="DDI-PubMed.32233814.s21.e2" text="AS-IV" /><pair ddi="false" e1="DDI-PubMed.32233814.s21.e2" e2="DDI-PubMed.32233814.s21.e2" /><pair ddi="false" e1="DDI-PubMed.32233814.s21.e2" e2="DDI-PubMed.32233814.s21.e0" /><pair ddi="false" e1="DDI-PubMed.32233814.s21.e2" e2="DDI-PubMed.32233814.s21.e1" /><pair ddi="false" e1="DDI-PubMed.32233814.s21.e0" e2="DDI-PubMed.32233814.s21.e0" /><pair ddi="false" e1="DDI-PubMed.32233814.s21.e0" e2="DDI-PubMed.32233814.s21.e1" /></sentence><sentence text="" /></document>